$0.952
+0.002 (+0.23%)收盤時
- 最高
- 1.050
- 開盤
- 1.010
- 成交量加權均價
- 0.98
- 成交量
- 151.70K
- 市值
- —
- 最低
- 0.950
- 成交金額
- 149.29K
- 企業價值/稅息折舊攤銷前利潤（TTM）
- 0.00
Veraxa Biotech AG is a Switzerland-based Company that develops antibody-based therapeutics for the treatment of cancer. The Company focuses on advancing proprietary platform technologies designed to generate targeted oncology therapies with improved safety and efficacy profiles. Its approach originates from scientific discoveries at the European Molecular Biology Laboratory, supporting the development of next-generation antibody-based drug candidates. The Company aims to expand treatment options for solid tumors by enabling more precise targeting mechanisms and potentially broader therapeutic windows compared with conventional therapies, addressing unmet needs across oncology markets through platform-driven innovation.
AI 分析 of Veraxa Biotech AG (VRXA)
買進Veraxa Biotech AG (VRXA) appears to be a good buy right now due to its recent positive news and potential for recovery. The stock has shown a 5.10% increase over the last five days, indicating a short-term upward trend. Additionally, the projected final change based on historical patterns is +93.44%, suggesting significant upside potential. However, the stock has a high risk, as it has declined 93.98% year-to-date, and its current price is only $1.03, which is near its 52-week low of $0.95. This high volatility and risk should be considered by investors.
估值指標
事件時間軸
資訊
3.510-13NewsfilterVERAXA Biotech Unveils Novel Cancer Therapy Data
- 3.510-09Newsfilter
VERAXA Biotech Advances New Approach Methodologies for Faster Clinical Development
5.009-04NASDAQ.COMVERAXA Biotech Appoints New CFO Raju Willener
- 5.009-04Newsfilter
VERAXA Appoints New Chief Financial Officer
7.508-24NASDAQ.COMVERAXA and Secarna Report Positive Results in AOC Development
VRXA 常見問題 —— 由 Alphio AI 解答
Veraxa Biotech AG is a Switzerland-based Company that develops antibody-based therapeutics for the treatment of cancer. The Company focuses on advancing proprietary platform technologies designed to generate targeted oncology therapies with improved safety and efficacy profiles. Its approach originates from scientific discoveries at the European Molecular Biology Laboratory, supporting the development of next-generation antibody-based drug candidates. The Company aims to expand treatment options for solid tumors by enabling more precise targeting mechanisms and potentially broader therapeutic windows compared with conventional therapies, addressing unmet needs across oncology markets through platform-driven innovation. It operates in the Healthcare sector.
Veraxa Biotech AG (VRXA) appears to be a good buy right now due to its recent positive news and potential for recovery. The stock has shown a 5.10% increase over the last five days, indicating a short-term upward trend. Additionally, the projected final change based on historical patterns is +93.44%, suggesting significant upside potential. However, the stock has a high risk, as it has declined 93.98% year-to-date, and its current price is only $1.03, which is near its 52-week low of $0.95. This high volatility and risk should be considered by investors.
社群
更多 ↗暫無貼文
註冊或登入後參與討論相關文章
- How to Rebalance a Concentrated Stock Portfolio in 2026: Mag7 Drift, Tax-Aware Trims, and Practical Rebalance a concentrated stock portfolio in 2026: Mag7 drift risk, 5pp bands, tax-aware trims, RSP/IWM diversifiers, and single-name caps.
- Small Cap Stocks Investing Guide 2026: Russell 2000, Fed Hikes, and the Financing TradeSmall-cap stocks investing guide 2026: Russell 2000 vs S&P, IWM rate sensitivity, floating-rate debt, Fed hikes, valuation discounts, and a practical checklist.
- Santa Claus Rally and the Year-End Stock Market: Investor Guide for Late 2026Santa Claus rally explained: 7-day window stats since 1950, Nov–Dec seasonality, post-midterm 2026 setup, and a risk-managed year-end investing playbook.
本頁僅供研究參考，不構成投資建議。模型可能出錯。過往表現不代表未來結果。